Chasing Astellas, UK's KaNDy heads to phase 3 with menopause...

UK biotech KaNDy Therapeutics is heading to phase 3 with its non-hormonal menopause drug, after a mid-stage trial showed it reduced hot flashes as well as improved quality of life, setting

Neurocrine signs $400M-plus deal with Idorsia for epilepsy d...

FDA approves Allergan's migraine tablet ahead of AbbVie merg...

Allergan’s migraine tablet Ubrelvy (ubrogepant) has been approved in the US for the acute treatment of patients with or without aura.

Neurocrine and Xenon agree $1.75bn epilepsy R&D tie-up

Two biotechs, Neurocrine Biosciences and Xenon, have announced a licence and collaboration agreement to develop first-in-class treatments for epilepsy in a deal worth up to $1.75 billion.

Alkermes bolts on Rodin Therapeutics to bulk up thin pipelin...

Merck builds in CNS diseases with $576m Calporta buy